Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Hester Biosciences

HESTERBIO
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Hester Biosciences Share price and Fundamental Analysis

View All Details
View All Details
Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. Since its incorporation in Apr' 87, the Company has been engaged in the production and distribution of vaccines and health products. Headquartered in Ahmedabad, Gujarat, the Company is currently the second-largest maker of poultry vaccines in India, having acquired strong brand equity over the years.
Company Incorporation1987
ChairmanBhupendra V Gandhi
Head QuartersAhmedabad
Previous NameNA

Key Metrics

Market Cap (Cr)
1,494.19
PE Ratio
54.36
Industry P/E
35.21
PEG Ratio
1.19
ROE
8.75%
ROCE
8.99%
ROA
4.41%
Total Debt (Cr)
104.27
Debt to Equity
0.68
Dividend Yield
0.4%
EPS
32.31
Book Value & P/B
398.6 x 4.41
Face Value
10
Outstanding Shares(Cr)
0.85
Current Ratio
3.84
EV to Sales
5.47

Included In

+More

Stock Returns

1 Week-4.42%
1 Month-3.26%
6 Months-26.81%
1 Year-31.22%
3 Years-13.02%
5 Years+45.19%
no_data

No Stocks

Smart Score

1.7
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 53.73%

FIIs : 0.87%

DIIs : 0.02%

Public : 45.38%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Increased by 0.28% to 0.87% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Hester Biosciences Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Hester Biosciences Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. Since its incorporation in Apr' 87, the Company has been engaged in the production and distribution of vaccines and health products. Headquartered in Ahmedabad, Gujarat, the Company is currently the second-largest maker of poultry vaccines in India, having acquired strong brand equity over the years.

The Company principally engages in two business verticals, namely Poultry Healthcare and Animal Healthcare. Its products are registered with several countries, and internal agencies, and have gained widespread recognition in both India and international markets. It has built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh. The products and services offered include over 51 vaccines and 70+ health products. In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals.

The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan; Maine Biological Laboratories, US; Idexx Corporation, US; International Diagnostic Systems Corporation, US; Biogal Galed Laboratories, Israel; and Kemin Europa, Belgium.

The company's own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation.

During 1996-97, company successfully implemented veterinary vaccine and commercial production has begun.

The company received licenses for producing 10 additional poultry vaccines. It signed a manufacturing agreement with Sinsui Inc for producing poultry vaccines.

In 2003, Hester was appointed as the exclusive Indian distributor by BIOPHARM of Czech Republic, for their coccidiosis vaccine - LIVACOX.

Hester commenced business with Merial in the 3rd quarter of the financial year by importing poultry vaccines from them in 2004-05 and therefore, name of Company was changed from HESTER PHARMACEUTICALS LIMITED to HESTER BIOSCIENCES LIMITED. The Company embarked on an expansion program, to increase its capacity from 1200 million doses to 4800 million doses, which was commenced in January 2006. The expansion project and the new expanded capacity went on-stream in March 2007. The distribution network within India was made functional with company managed depots at Pune, Bangalore, Coimbatore, Hyderabad and Chandigarh, having state-of-art cold store facilities to maintain the cold chain. Distribution costs were further cut by embarking on the use of company owned refrigerated vans for deliveries all across India.

In January 2010, the company re-launched the freeze dried MD Vaccine after 5 years. A JV was set-up in Nepal to facilitate manufacture of specific animal vaccines for international markets in 2011 for a project which costed Rs 15 crores. New technology was acquired. The Company signed a technology transfer agreement with Indian Veterinary Research Institute for acquiring technology to manufacture PPR and Sheep Pox vaccines in 2011.

Company re-launched the bivalent Marek's Disease Live vaccine for the poultry, containing HVT & SB1 strains in 2012-13. It operationalised large animal vaccines division in Mar' 15. During the financial year 2014-15, Gujarat Agrofarm Limited became a wholly owned subsidiary of the Company.

During financial year 2015-16, three wholly owned subsidiary Companies namely Gujarat Agrofarm Limited, Diavetra Lifesciences Private Limited and Hester Biosciences (Mauritius) Limited got merged with Company through a Scheme of Arrangement effective on 8 December 2015. Accordingly, the Company allotted and listed its 65 Equity Shares pursuant to Scheme of Arrangement vide order passed by Hon'ble High Court of Gujarat dated 8 December 2015 and the said Shares were listed at NSE Limited and BSE Limited in March, 2016. Leruarua Vetcare (Proprietary) Limited, incorporated in Botswana became an Associate Company with 49% stake of the Company and Innoves Animal Health Private Limited ceases to be an Associate Company due to transfer of shareholding of the Company in FY 2015-16.

The Nepal unit completed trial operations and began commercial manufacturing in November, 2016. Leruarua Vetcare (Proprietary) Limited, Botswana ceases to be an Associate Company due to buyback of entire shareholding by the Associate Company during the FY 2016-17. The Company held 65% stake in subsidiary Company, Hester Biosciences Nepal Private Limited (HBNPL) and consequently, HBNPL became a subsidiary of Hester Biosciences Limited (Parent Company) during FY 2016-17.

During the year 2017-18, Company acquired 54.80% in the capital of Texas Laboratories, a firm having a business place at Mehsana Distt. of Gujarat. In June 2017, Texas Laboratories converted into Private Limited Company namely, Texas Lifesciences Private Limited. Further, the Company incorporated 100% wholly-owned subsidiary, Hester Biosciences Africa Limited in Tanzania.

During the year 2018-19, Hester Biosciences Limited incorporated 100% wholly-owned subsidiary Hester Biosciences Kenya Limited in Kenya.

Hester Biosciences Share Price

Hester Biosciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Hester Biosciences Market Cap

Market capitalization of Hester Biosciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Hester Biosciences is valued compared to its competitors.

Hester Biosciences PE Ratio

Hester Biosciences PE ratio helps investors understand what is the market value of each stock compared to Hester Biosciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Hester Biosciences PEG Ratio

The PEG ratio of Hester Biosciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Hester Biosciences ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Hester Biosciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Hester Biosciences ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Hester Biosciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Hester Biosciences Total Debt

Total debt of Hester Biosciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Hester Biosciences Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Hester Biosciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Hester Biosciences CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Hester Biosciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Hester Biosciences Technical Analysis

Technical analysis of Hester Biosciences helps investors get an insight into when they can enter or exit the stock. Key components of Hester Biosciences Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Hester Biosciences shares often struggle to rise above due to selling pressure.

Hester Biosciences Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Hester Biosciences ’s financial health and profitability.

Hester Biosciences Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Hester Biosciences Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Hester Biosciences Financials

The financials of Hester Biosciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Hester Biosciences Profit and Loss Statements

The profit and loss statement of Hester Biosciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Hester Biosciences .

Hester Biosciences Balance Sheet

The balance sheet presents a snapshot of Hester Biosciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Hester Biosciences Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App